Citadel Advisors’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-33,600
Closed -$42.3K 13123
2025
Q3
$42.3K Sell
33,600
-27,500
-45% -$29.7K ﹤0.01% 12271
2025
Q2
$68.4K Buy
61,100
+34,400
+129% +$40K ﹤0.01% 11605
2025
Q1
$21.1K Buy
26,700
+10,900
+69% +$13.4K ﹤0.01% 13104
2024
Q4
$26.1K Buy
15,800
+12,100
+327% +$30.5K ﹤0.01% 12997
2024
Q3
$12.9K Buy
3,700
+600
+19% +$2.33K ﹤0.01% 13079
2024
Q2
$10.2K Sell
3,100
-10,400
-77% -$45.5K ﹤0.01% 13101
2024
Q1
$99.1K Buy
13,500
+12,000
+800% +$74.3K ﹤0.01% 11369
2023
Q4
$5.61K Buy
1,500
+600
+67% +$1.42K ﹤0.01% 13416
2023
Q3
$1.91K Sell
900
-8,000
-90% -$26.5K ﹤0.01% 13787
2023
Q2
$42.4K Sell
8,900
-12,600
-59% -$69.5K ﹤0.01% 12004
2023
Q1
$123K Sell
21,500
-11,100
-34% -$67K ﹤0.01% 10971
2022
Q4
$329K Sell
32,600
-3,700
-10% -$69.5K ﹤0.01% 9114
2022
Q3
$813K Buy
36,300
+5,800
+19% +$168K ﹤0.01% 7439
2022
Q2
$756K Buy
30,500
+8,300
+37% +$229K ﹤0.01% 7676
2022
Q1
$861K Sell
22,200
-20,300
-48% -$786K ﹤0.01% 8045
2021
Q4
$2.49M Buy
42,500
+16,800
+65% +$952K ﹤0.01% 5741
2021
Q3
$1.52M Sell
25,700
-7,500
-23% -$588K ﹤0.01% 7048
2021
Q2
$2.88M Sell
33,200
-39,300
-54% -$3.17M ﹤0.01% 5700
2021
Q1
$5.98M Buy
72,500
+32,200
+80% +$3.09M 0.01% 3874
2020
Q4
$3.66M Buy
40,300
+11,300
+39% +$702K ﹤0.01% 4236
2020
Q3
$1.16M Sell
29,000
-2,400
-8% -$83.8K ﹤0.01% 5762
2020
Q2
$1.08M Buy
31,400
+8,200
+35% +$244K ﹤0.01% 5705
2020
Q1
$515K Buy
23,200
+10,100
+77% +$255K ﹤0.01% 6416
2019
Q4
$256K Sell
13,100
-1,000
-7% -$15.9K ﹤0.01% 7832
2019
Q3
$219K Sell
14,100
-9,500
-40% -$182K ﹤0.01% 8036
2019
Q2
$479K Sell
23,600
-11,500
-33% -$207K ﹤0.01% 6884
2019
Q1
$617K Buy
35,100
+16,000
+84% +$253K ﹤0.01% 6418
2018
Q4
$245K Sell
19,100
-1,200
-6% -$16.7K ﹤0.01% 7579
2018
Q3
$331K Buy
20,300
+3,200
+19% +$37.8K ﹤0.01% 7409
2018
Q2
$194K Buy
+17,100
New +$188K ﹤0.01% 7910

Other funds holding FATE